Duolingo Officer Stephen Chen Files to Sell 3,700 Shares
Stephen Chen of Duolingo, Inc. has filed to sell 3,700 shares of common stock, reflecting personal financial decisions amidst ongoing insider sales.
BNY Mellon ETF Trust Announces Investment Adviser Consolidation
BNY Mellon ETF Trust plans to consolidate its investment advisory firms into BNY Investments Corporation, effective January 1, 2027.
BNY Mellon Advantage Funds to Consolidate Investment Advisers
BNY Mellon Advantage Funds, Inc. announces plans to consolidate its investment advisory firms into BNY Investments Corporation effective January 1, 2027.
Koren Ofer Sells 12,500 Shares of Global-E Online Ltd.
Koren Ofer sells 12,500 shares of Global-E Online Ltd., valued at $519,750, reflecting ongoing stock management strategies.
Dreyfus Institutional Reserves Funds Announces Adviser Consolidation
Dreyfus Institutional Reserves Funds will consolidate advisers under BNY Investments Corporation, effective January 1, 2027, enhancing operational efficiency.
F5, Inc. Officer Files to Sell 1,297 Shares of Stock
Michael Montoya of F5, Inc. has filed to sell 1,297 shares, valued at over $429,000, reflecting insider activity in the tech sector.
BlackRock Funds to Reorganize Advantage Fund into ETF
BlackRock Funds announces the reorganization of its Advantage Large Cap Growth Fund into an ETF, aiming to enhance investor benefits and reduce expenses.
BNY Mellon ETF Trust to Consolidate Investment Advisers
BNY Mellon ETF Trust announces adviser consolidation to streamline operations, effective January 1, 2027. No shareholder vote required.
BNY Mellon Advantage Funds Announces Adviser Consolidation
BNY Mellon Advantage Funds, Inc. will consolidate its investment firms into BNY Investments Corporation effective January 1, 2027, enhancing brand identity and operations.
Barbara J. Comly to Sell 150,466 Shares of Miami Holdings
Barbara J. Comly files to sell 150,466 shares of Miami International Holdings, reflecting ongoing market activity in the security brokerage industry.
Frank Mottola appointed Chief Technical Operations Officer at Supernus
Frank Mottola has been appointed as Senior VP and Chief Technical Operations Officer at Supernus, reflecting a key leadership change in the pharmaceutical industry.
Supernus, Inc. Updates SEC Filing on Executive Ownership
Supernus, Inc. updates SEC filing reflecting changes in executive ownership, highlighting shifts in leadership within the pharmaceutical preparations sector.
Horich William Todd Files Form 3 as Chief Commercial Officer
Horich William Todd has filed a Form 3, indicating his role as Chief Commercial Officer at Supernus, Inc., marking a significant step for the company.
Jonathan Rubin Files Form 3 as Chief Medical Officer at Supernus
Jonathan Rubin has filed a Form 3 as Chief Medical Officer at Supernus, reflecting ongoing leadership and ownership transparency in the pharmaceutical industry.
Sensenig Bethany Reports Change in Ownership Status
Sensenig Bethany reports no beneficial ownership of Supernus, Inc. securities, reflecting ongoing changes in the pharmaceutical preparations sector.
Georges Gemayel Joins Supernus, Inc. as New Director
Georges Gemayel has been appointed as a director at Supernus, Inc., signaling potential strategic shifts for the pharmaceutical company.
RPC Inc. Director Acquires 15,255 Shares in Equity Grant
John F. Wilson of RPC Inc. acquires 15,255 shares as equity compensation, reflecting strong alignment with shareholder interests.
Miller Robert sells 1,817 shares of LCNB Corp stock
Michael Robert Miller, Executive VP of LCNB Corp, sells 1,817 shares of common stock, reducing his holdings. The banking sector remains competitive.
Ibotta CTO Swanson Luke Roy Sells Significant Shareholdings
Swanson Luke Roy, CTO of Ibotta, Inc., sold thousands of shares in recent transactions, reflecting strategic financial moves in the tech industry.
Bhatt Padmanabh P. Reports Transactions After Supernus Merger
Bhatt Padmanabh P. discloses significant stock transactions following the merger of Supernus Pharmaceuticals with Indivior Pharmaceuticals. Read more.